slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
223,861-223,890 of 319,975
02
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
03
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
04
The slide highlights clinical validation through trial count and patient numbers, alongside key product attributes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a Gantt-style visualization to show the status of multiple clinical trials.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
06
Uses a process diagram to show the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
07
The central diagram illustrates the mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
08
Uses a pyramid diagram to represent the progression of clinical validation.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
09
The slide compares mPFS results against SOC-AURELIA and ELAHARE benchmarks.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
10
The slide outlines the methodology and validation of a clinical trial.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide uses a table to compare clinical outcomes across patient subgroups (all, resistant, refractory) and a callout box for key takeaways.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Waterfall plot and spider plot used to visualize clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
13
The slide uses a before-after comparison structure for three specific patient cases (15B-01, 15B-15, 15B-17).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
14
Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) showing tumor response metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
The slide uses a document-style callout for key takeaways and circular image containers for facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
The slide categorizes the library into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
26
The slide uses a grid layout to present headshots, names, titles, and associated company/institution logos for each team member.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Team1 hit
27
Includes specific financial metrics and analyst names.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track timeline approach: one for executed milestones (left) and one for future goals (right).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit